

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	09890335
Filing Date	2002-04-08
First Named Inventor	Cevc
Art Unit	1645
Examiner Name	B.J. Gangle
Attorney Docket Number	

U.S. PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	6448296	A1	2002-09-10	Yasueda et al.	
	2	6451339	A1	2002-09-17	Patel et al.	
	3	6562370	A1	2003-05-13	Luo et al.	
	4	6582724	A1	2003-06-24	Hsu et al.	
	5	6586000	A1	2003-07-01	Luo et al.	
	6	6645520	A1	2003-11-11	Hsu et al.	
	7	6645529	A1	2003-11-11	Gergely et al.	
	8	6726598		2004-04-27	Jarvis et al.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		09890335
Filing Date		2002-04-08
First Named Inventor	Cevc	
Art Unit	1645	
Examiner Name	B.J. Gangle	
Attorney Docket Number		

9	6835392	A1	2004-12-28	Hsu et al.	
10	RE33273		1990-07-24	Speaker	
11					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S. PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	93/19737	WO		1993-10-14	Kabi Pharmacia AB		<input type="checkbox"/>
	2	05/063213	WO		2005-07-14	Biodelivery Sciences International, Inc.		<input type="checkbox"/>
	3	95/09831	WO		1995-04-13	Nicox Ltd. et al.		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		09890335
Filing Date		2002-04-08
First Named Inventor	Cevc	
Art Unit	1645	
Examiner Name	B.J. Gangle	
Attorney Docket Number		

4	06/050926	WO		2006-05-18	IDEA AG		<input type="checkbox"/>
5	02/32398	WO		2002-04-25	Massachusetts Institute of Technology		<input type="checkbox"/>
6	98/33483	WO		1998-08-06	Depotech Corporation		<input type="checkbox"/>
7	93/19736	WO		1993-10-14	Kabi Pharmacia AB		<input type="checkbox"/>
8	01/01962	WO		2001-01-11	IDEA Innovative GmbH		<input type="checkbox"/>
9	90/11065	WO		1990-10-04	Theratec, Inc.		<input type="checkbox"/>
10	00/13684	WO		2000-03-16	Loma Linda University Medical Center		<input type="checkbox"/>
11	94/26257	WO		1994-11-24	LTS Lohmann Therapie-Systeme GmbH & Co.		<input checked="" type="checkbox"/>
12	00/12060	WO		2000-03-09	Cevc		<input type="checkbox"/>
13	92/05771	WO		1992-04-16	Kabi Pharmacia		<input type="checkbox"/>
14	99/22703	WO		1999-05-14	Lurident Ltd.		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		09890335
Filing Date		2002-04-08
First Named Inventor	Cevc	
Art Unit	1645	
Examiner Name	B.J. Gangle	
Attorney Docket Number		

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	1	Karzel and R.K. Liedtke, "Mechanism Transkutaner Resorption." on Grundlagen/Basics, pp. 1487-1491	<input checked="" type="checkbox"/>
	2	Katoulis et al., "Efficacy of a new needleless insulin delivery system monitoring of blood glucose fluctuations and free insulin levels," on International J. of Artificial Organs 12(5):333-338 (1989)	<input type="checkbox"/>
	3	Klibanov, et al., "Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target," BBA 1062:142-148 (1991)	<input type="checkbox"/>
	4	Knepp et al., "Controlled drug release from a novel liposomal delivery system II. Transdermal delivery characteristics," J. Contr. Release 12(1):25-30 (Mar. 1990) Amsterdam, NL	<input type="checkbox"/>
	5	Lasch, J. et al., "Interactions of external lipids (lipid vesicles) with the skin" J. Liposome Research 5(3):543-569 (1995)	<input type="checkbox"/>
	6	Lehmann, J. et al., "Analgesic and anti-inflammatory efficacy of IDEA-070 in UVB-induced sunburn." J. Eur. Acad. Dermatol. Venereol. 18(S2):267-268 (Oct. 2004)	<input type="checkbox"/>
	7	Lichtenberg, D. et al., "Solubilization of phospholipids by detergents: structural and kinetic aspects" BBA 737:285-304 (1983)	<input type="checkbox"/>
	8	Lobbecke, et al., "Effects of short-chain alcohols on the phase behavior and interdigitation of phosphatidylcholine bilayer membranes" BBA 1237:59-69 (1995)	<input type="checkbox"/>
	9	Mayer, L.D. et al., "Vesicles of variable sizes produced by a rapid extrusion procedure," BBA 858:161-168 (1986)	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		09890335
Filing Date		2002-04-08
First Named Inventor	Cevc	
Art Unit	1645	
Examiner Name	B.J. Gangle	
Attorney Docket Number		

10	Merck Index: 10th Edition, 1983. Pages 779-780.	<input type="checkbox"/>
11	Mezei, "Liposomes as a skin drug delivery system," 1985 Elsevier Science Publishers B.V. (Biomedical Division) pp.345-358	<input type="checkbox"/>
12	Ogiso, Taro et al., "Membrane-controlled transdermal therapeutic system containing clonazepam and anticonvulsant activity after its application," Chem. Pharm. Bull. 37(2):446-449 (1989)	<input type="checkbox"/>
13	Patel, H.M. et al., "Oral administration of insulin by encapsulation within liposomes," FEBS Letters 62(1):60-63 (Feb. 1976)	<input type="checkbox"/>
14	Patel, H.M., "Liposomes as a controlled-release system," Biomedical Society Transactions 609th Meeting, Leeds, pp.513-516.	<input type="checkbox"/>
15	Peters, et al., "Pharmacodynamics of a liposomal preparation for local anaesthesia," Arzneimittel-Forsch/Drug Res. 45(II), Nr12 (1995), pages 1253-56	<input type="checkbox"/>
16	Planas, et al., "Noninvasive percutaneous induction of topical analgesia by a new type of drug carrier, and prolongation of local pain insensitivity by anesthetic liposomes," Anesth. Analg. 75:615-621 (1992)	<input type="checkbox"/>
17	Price, C.E., "A review of the factors influencing the penetration of pesticides through plant leaves," on I.C.I. Ltd., Plant Protection Division, Jealott's Hill Research Station, Bracknell, Berkshire RG12 6EY, U.K., pp. 237-252	<input type="checkbox"/>
18	Product Information: "Polysorbate 80 VG" (2004)	<input type="checkbox"/>
19	Product Information: "Tween 80 Pure" (2004)	<input type="checkbox"/>
20	Prof. Dr. K-U Benner, Der Körper des Menschen, "The human body" Weltbild GmbH Augsburg Chapter 4 page 49 (1995)	<input checked="" type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		09890335
Filing Date		2002-04-08
First Named Inventor	Cevc	
Art Unit	1645	
Examiner Name	B.J. Gangle	
Attorney Docket Number		

21	Ranade V., "Drug delivery systems. 6. Transdermal drug delivery," J. Clin. Pharmacol. 31:401-418 (1991)	<input type="checkbox"/>
22	Roeding, J. "Liposomes and niosomes in pharmacy and cosmetics state of art prospects, techniques of visualizing vesicular systems, interaction of liposomes with the skin" Training course no. 105 from May 14-16, 1990, Maritim Hotel Nurnberg, Frauentorgraben 11, 8500, Nurnberg.	<input type="checkbox"/>
23	Schramlova, J. et al., "The effect of an antiphlogistic incorporated in liposomes on experimentally induced inflammation," Folia Biologica (Praha) 43:195-199 (1997)	<input type="checkbox"/>
24	Schreier, H. "Liposomes - A novel drug carrier. I. Phospholipids; production and characterization of liposomes; II. Destiny of liposomes in vivo; use in therapy," Pharmazie in unserer Zeit, No. 4 (1982)	<input type="checkbox"/>
25	SERVA Feinbiochemica, Katalog, pages 201-202 (1986/1987)	<input type="checkbox"/>
26	Siddiqui, O. et al., "Nonparenteral administration of peptide and protein drugs," CRC Critical Review in Therapeutic Drug Carrier Systems, Vol. 3, Issue 3 pg. 195-208	<input type="checkbox"/>
27	Stoye, I. et al., "Transformation of a liposomal dispersion containing ibuprofen lysinate and phospholipids into mixed micelles - physico-chemical characterization and influence on drug permeation through excised human stratum corneum," Eur. J. Pharmaceuticals and Biopharmaceuticals 46:191-200 (1998)	<input type="checkbox"/>
28	Swenson, E. Scott and William J. Curatolo, "Intestinal permeability enhancement for proteins, peptides and other polar drugs: mechanisms and potential toxicity" Advanced Drug Delivery Reviews, 8:39-92 (1992)	<input type="checkbox"/>
29	Trotta, M. et al., "Deformable liposomes for dermal administration of methotrexate," International J. of Pharmaceutics (Kidlington) 270(1-2) 11 Feb 2004, pages 119-125	<input type="checkbox"/>
30	Trotta, M. et al., "Elastic liposomes for skin delivery of dipotassium glycyrrhizinate," International J. of Pharmaceutics (Kidlington) 241(2) 25 Jul 2002, pages 319-327	<input type="checkbox"/>
31	Valenta, C. et al. "Evaluation of novel soya-lecithin formulations for dermal use containing ketoprofen as a model drug," J. Contr. Release 63:165-173 (2000)	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		09890335
Filing Date		2002-04-08
First Named Inventor	Cevc	
Art Unit	1645	
Examiner Name	B.J. Gangle	
Attorney Docket Number		

32	Vinggaard, A.M., et al., "Didecanoyl phosphatidylcholine is a superior substrate for assaying mammalian phospholipase D." Biochem. J. 319:861-864 (1996)	<input type="checkbox"/>
33	Vinson, P. et al., "Vesicle-micelle transition of phosphatidylcholine bilayers and octylglucoside elucidated by cryo-transmission electron microscopy," Biophys. J., Biophysical Society Vol. 56, October 1989 pages 669-681.	<input type="checkbox"/>
34	Vyas et al., "Liposomally encapsulated diclofenac for sonophoresis induced systemic delivery," J. Microencapsulation, 1995, 12(2):149-154.	<input type="checkbox"/>
35	Wearley LL, "Recent progress in protein and peptide delivery by noninvasive routes." Crit. Rev. Ther. Drug Carrier Syst. 8:331-94 (1991)	<input type="checkbox"/>
36	Wess, L., "All in the Family." Biocentury, the Bernstein Report on Biobusiness, 12(22):A11-A12 17 May 2004 (2004-05-17)	<input type="checkbox"/>
37	Yuan, et al., "Cationic liposome and gene transfer," Progress in Physiological Science, 28(2): 163-165 (1997) (English translation only)	<input checked="" type="checkbox"/>
38	Jackson, M.L. et al., "Solubilization of phosphatidylcholine bilayers by octyl glucoside" Biochemistry 21:4576-4582 (1982)	<input type="checkbox"/>
39	English language abstract of EP 0 298 280 A from Derwent	<input type="checkbox"/>
40	English language abstract of EP 0 102 324 from Derwent	<input type="checkbox"/>
41	Pierson et al., "Synthesis and biological evaluation of potent, selective, hexapeptide CCK-A agonist anorectic agents" J. Med. Chem. 40:4302-07 (1997)	<input type="checkbox"/>
42	Lee et al., "Intranasal bioavailability of insulin powder formulations: Effect of permeation enhancer-to-protein ratio" J. Pharm. Sci. 80(8):725-29 (1991)	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT****(Not for submission under 37 CFR 1.99)**

Application Number	09890335
Filing Date	2002-04-08
First Named Inventor	Cevc
Art Unit	1645
Examiner Name	B.J. Gangle
Attorney Docket Number	

43	Shao et al., "Cyclodextrins as nasal absorption promoters of insulin: Mechanistic evaluations" Pharm. Res. 9 (9):1157-63 (1992)	<input type="checkbox"/>
44	Illum et al., "Chitosan as a novel nasal delivery system for peptide drugs" Pharm. Res. 11(8):1186-89 (1994)	<input type="checkbox"/>
45	Lowell et al., "Proteosomes, emulsomes, and cholera toxin B improve nasal immunogenicity of human immunodeficiency virus gp160 in mice: Induction of serum, intestinal, vaginal, and lung IgA and IgG" J. Infect. Dis. 175:292-301 (1997)	<input type="checkbox"/>
46	Schreier et al., "Liposomen - ein neuartiger Arzneistoffträger II. Schicksal von Liposomen in vivo" Einsatz in der Therapie", Pharmazie in unserer Zeit No. 4 (1982), pages 103-108	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Brian Gangle/	Date Considered	08/11/2010
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.